NCT03391739Unknown2 期
CART-19 Cells For Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Fujian Medical University1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2016年1月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Leukemia free survival
研究概览
简要总结
There are limited treatment options for relapse/refractory B-cell acute lymphoblastic leukemia(ALL). However,CART-19 cells has emerged as a powerful targeted immunotherapy for highly refractory CD19+ acute lymphoblastic leukemia (ALL). This study aims to assess the safety and toxicity of CART-19 cells to patients with relapse/refractory B-cell ALL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 60 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent
- •Aged between 1-60 years
- •Patients with relapsed/refractory B-cell ALL
- •Cardiac: Left ventricular ejection fraction ≥ 50%
- •Adequate renal and hepatic function
- •Performance status: Karnofsky ≥ 70%
排除标准
- •Pregnant or lactating females.
- •Any co-morbidity precluding the administration of CART-19 cells.
研究组 & 干预措施
Arm 1
Experimental
CART-19 cells treat
干预措施: CART-19 cells (Biological)
结局指标
主要结局
Leukemia free survival
时间窗: 1 year
次要结局
- Adverse events that are related to treatment(1 year)
研究者
Jianda Hu
Director of the department of Hematology
Fujian Medical University
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
CART-19 Cells for R/R B-cell LymphomaRelapsed or Refractory B-cell LymphomaNCT03391726Fujian Medical University20
Unknown
2 期
CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)Relapsed/Refractory AMLNCT03631576Fujian Medical University20
招募中
1 期
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid LeukemiaLeukemia, MyeloidLeukemiaLeukemia, Myeloid, AcuteNCT04265963Chongqing Precision Biotech Co., Ltd45
Unknown
1 期
The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).B-cell Acute Lymphoblastic LeukemiaNCT02924753Henan Cancer Hospital20
招募中
2 期
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic LeukemiaB-cell Acute Lymphoblastic LeukemiaDiffuse Large B Cell LymphomaB-cell LymphomaNCT06081478Beijing Tongren Hospital100